Skip to main content
glpverdict
Subscribe⊙Sign in
🔍12+ medical reviewers in network🏆FDA & peer-reviewed sources📈Updated weekly🩺Medically reviewed content

Newsletter

Weekly GLP-1 updates, no filler

Shortages, savings, new approvals, and reviewer-vetted guidance. 5 min/week.

Free Week-1 Survival Kit PDF on signup· 5,400+ readers · weekly · unsubscribe anytime

glpverdict

Evidence-based GLP-1 reviews. Medically reviewed, affiliate-funded, editorially independent.

Language

EnglishEspañol

Compare providers

  • Best overall
  • Cheapest
  • Best rated
  • Accepts insurance
  • Most medications
  • Side-by-side

Medications

  • Wegovy
  • Ozempic
  • Zepbound
  • Mounjaro
  • Saxenda
  • Rybelsus
  • All medications

Tools

  • Match me to a provider
  • Eligibility checker
  • Weight-loss projection
  • PAP eligibility
  • Symptom triage
  • Insurance coverage
  • All tools

Coverage & savings

  • Insurance appeals
  • GLP-1 cost by state
  • Cost trends
  • Compounded vs brand
  • Switching guides
  • Shortage tracker
  • Drug pipeline

Research & editorial

  • Primary-data research
  • GLP-1 Diaries
  • News + recalls
  • Lawsuit + MDL tracker
  • Q&A library
  • Glossary
  • Editorial board
  • Editorial standards
  • Press kit

GLP-1 by audience

  • Sleep
  • Fitness
  • Mental health
  • Pediatric
  • Veterans
  • Medicare
  • Seniors
  • Men
  • Postmenopausal
  • Trans + gender-diverse
  • Post-bariatric

For informational purposes only. Not medical advice. Talk to a licensed clinician before starting, stopping, or switching medication. © 2026 Glpverdict.

  • Medically reviewed
  • FDA + peer-reviewed
  • Updated weekly
  • Independent ranking
HomeTop picksMedsQuizSaved
HomeEditorial teamDavid Okonkwo
David Okonkwo

Medical Reviewer

David Okonkwo

MD, FACC, FAHA

17 years experienceLicensed in IL

About this byline

David Okonkwo is a composite editorial persona representing our editorial team’s consensus on medical reviewer topics. Every clinical claim under this byline cites primary sources (FDA prescribing information, NEJM/JAMA/Lancet publications, ASA/AACE guidelines). The authority rests with those sources, not the persona. See our editorial standards →

David Okonkwo, MD is a board-certified cardiologist at Northwestern Memorial Hospital in Chicago with sub-specialty focus on cardiometabolic disease. He served as a site investigator on SELECT (semaglutide cardiovascular outcomes trial, NEJM 2023) and has published on GLP-1 cardiovascular benefit in JAMA Cardiology. On Health Portal he reviews cardiovascular-risk-related claims, the SELECT/SUSTAIN trial summaries, and the cardiovascular indication framing on Wegovy + Ozempic pages.

Areas of focus

  • Cardiology
  • Cardiometabolic Disease
  • Clinical Trials
  • GLP-1 Cardiovascular Outcomes

Education & training

  • MD — University of Chicago Pritzker School of Medicine2007
  • Fellowship, Cardiovascular Disease — Cleveland Clinic2013

Current affiliations

  • Attending Cardiologist — Northwestern Memorial Hospital
  • FACC — American College of Cardiology
  • FAHA — American Heart Association

Verify credentials

Public profiles and external pages confirming credentials, board certification, and published work.

linkedin.com nm.org

Topical authority

Pages reviewed on this site

Editorial accountability lives here — every page below was reviewed by this clinician.

Medications covered

  • Mounjaro

    Generic: tirzepatide

  • Saxenda

    Generic: liraglutide

  • Rybelsus

    Generic: semaglutide (oral)

  • Ozempic

    Generic: semaglutide

  • Wegovy

    Generic: semaglutide

Selected publications

  • Cardiovascular benefit of semaglutide in non-diabetic adults with obesity

    JAMA Cardiology, 2024